Efficacy of a basal insulin dose management smartphone application for controlling fasting blood glucose in patients with type-2 diabetes mellitus: A single-centre, randomised clinical study.

OBJECTIVE: To explore the efficacy and safety of the 'Walk with you' application for titrating basal insulin (BI) doses in type-2 diabetes mellitus (T2DM) hospitalised patients. METHODS: This was a randomised, single-centre, open-label, controlled clinical trial to compare the changes in fasting blood glucose (FBG) and postprandial blood glucose (PBG), time to reach target FBG (FBG-TRT), incidence of hypoglycaemia events and FBG coefficient of variation in the application group (weight-based titration of BI dose regimen) and control group (typical adjustment regimen). PATIENTS: This study selected 173 patients with T2DM using basal-prandial insulin therapy who were admitted to Binhaiwan Central Hospital of Dongguan between December 2021 and December 2022. Patients were randomised to the control group or the application group (App group) and then titrated to achieve an FBG concentration of less than 7.0 mmol/L. RESULTS: There were 86 patients in the control group and 87 patients in the App group. The FBG concentrations in the control and App groups were decreased by 6.77 ± 4.75 and 5.95 ± 4.06 mmol/L, respectively. The FBG-TRTs in the control and App groups were 3.80 ± 1.52 and 2.82 ± 1.34 days, respectively (p < .001). Fewer patients in the control group reached the FBG-TRT within 3 days than in the App group, with 46.5% and 71.3% of patients reaching that target, respectively. There was no significant between-group difference in hypoglycaemia incidence. CONCLUSION: The use of this weight-based insulin dose titration protocol for BI app is effective and safe for achieving the target FBG in noncritically ill patients with T2DM and is free, easy to use and user friendly.

Circ_0091581 Promotes the Progression of Hepatocellular Carcinoma Through Targeting miR-591/FOSL2 Axis.

BACKGROUND: Circular RNAs (circRNAs) have shown crucial regulatory roles in cancer biology. We aimed to uncover the role and underlying mechanism of circ_0091581 in hepatocellular carcinoma (HCC) progression. METHODS: The abundance of circ_0091581, microRNA-591 (miR-591) and FOS like 2, AP-1 transcription factor subunit (FOSL2) was measured by quantitative real-time polymerase chain reaction. Cell viability, colony formation ability, and invasion ability were assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, colony formation assay, and transwell invasion assay. The migration ability was analyzed by transwell migration assay and wound healing assay. Flow cytometry was used to evaluate the cell cycle and apoptosis of HCC cells. The interaction between miR-591 and circ_0091581 or FOSL2 was predicted by Circular RNA Interactome database or TargetScan database and confirmed by dual-luciferase reporter assay and RNA immune co-precipitation assay. FOSL2 protein expression was measured by Western blot assay. Xenograft tumor assay was conducted to analyze the role of circ_0091581 in HCC tumor growth in vivo. RESULTS: Circ_0091581 was highly expressed in HCC tissue samples and cell lines in contrast to that in adjacent normal tissue samples and THLE-2 cell line. Circ_0091581 accelerated the viability, colony formation, metastasis, and cell cycle, while it impeded the apoptosis of HCC cells. MiR-591 bound to circ_0091581, and circ_0091581 knockdown-mediated effects in HCC cells were largely overturned by miR-591 silencing. FOSL2 was a target of miR-591, and FOSL2 overexpression largely reversed miR-591 accumulation-induced influences in HCC cells. FOSL2 protein expression was down-regulated by circ_0091581 silencing, and the addition of miR-591 inhibitor partly recovered the expression of FOSL2 in HCC cells. Circ_0091581 interference notably suppressed HCC tumor growth in vivo. CONCLUSION: Circ_0091581 acted as an oncogene to enhance the viability, colony formation, metastasis and cell cycle and inhibit the apoptosis of HCC cells through targeting miR-591/FOSL2 axis.

Nickel sulfide nanoworm network architecture as a binder-free high-performance non-enzymatic glucose sensor.

Nickel sulfide nanoworm (Ni3S2 NW) network architecture was directly grown on the poly (3,4-ethylenedioxythiophene)-reduced graphene oxide hybrid films (PEDOT-rGO HFs) modified on glassy carbon electrode (GCE), acting as a binder-free sensor for high-performance non-enzymatic glucose monitoring. The sensor exhibited the satisfactory sensitivity (2123 µA mM-1 cm-2), wide linear range (15~9105 µM), low detection limit (0.48 µM), and rapid response time (< 1.5 s) at a potential of 0.5 V (vs. SCE) in 0.1 M NaOH and possessed good selectivity, reproducibility, and stability. The enhanced electrocatalytic activity of the sensor towards glucose oxidation was attributed to the particular morphology, satisfying hydrophilic nature, strong combination between Ni3S2 NWs, PEDOT-rGO, and bare GCE. Moreover, it can be used for assaying glucose in human serum samples without dilution, indicating potential for clinical diagnostic applications. Graphical abstract Nickel sulfide nanoworms (Ni3S2 NWs)/poly (3,4-ethylenedioxythiophene)-reduced graphene oxide hybrid films (PEDOT-rGO HFs) were used to construct a binder-free high-performance non-enzymatic glucose sensor with satisfactory sensitivity, wide linear range, low detection limit, good selectivity, amazing reproducibility, and stability.

Curly fish scales-like Ni2.5Mo6S6.7 electrodeposited on PEDOT-rGO with uneven surface as ultrafast response electrode for electrocatalytic glucose, nitrite and hydrogen peroxide.

The difficulty to achieve rapid detection is the limitation of many enzyme-free sensors today. Thus, designing tri-functionalsensors with ultra-fast and efficientdeterminationis a challenging taskin biological science. Herein, curly fish scales-like Ni2.5Mo6S6.7 active materials was anchored on poly (3,4-ethylenedioxythiophene)-reduced graphene oxide (PEDOT-rGO) hybrid membranes with uneven surface (Ni2.5Mo6S6.7/PEDOT-rGO) as a high-performance tri-functional catalyst for glucose, nitrite and hydrogen peroxide determination.The sensor constructed under optimal conditions exhibited ultrafast response performance towards glucose and nitrite within 2 s, and hydrogen peroxide within 1 s. Meanwhile, it provided the wide linear range with a low detection limit towards glucose (as low as 0.001 mM and up to 15.000 mM, and 0.33 µM), nitrite (as low as 0.001 mM and up to 10.000 mM, and 0.33 µM) and hydrogen peroxide (from 0.010 mM to 7.000 mM, and 0.79 µM), respectively. In addition, the sensor demonstrated satisfied selectivity, repeatability, reproducibility and stability. Furthermore, the sensor has potential application in real samples. This study may provide a new strategy for the construction of tri-functional electrode materials with the ultra-fast response.

Meta-analysis of the prognostic value of pretreatment serum ferritin in hepatobiliary and pancreas (HBP) cancers.

BACKGROUND AND OBJECTIVES: Studies have shown that serum ferritin (SF) has unfavourable prognostic value in hepatobiliary and pancreas (HBP) cancers. This meta-analysis aimed to comprehensively assess the prognostic role of pretreatment SF in patients with HBP cancers. METHODS: Eligible studies published before January 2020 were obtained through a comprehensive search in the PubMed, Web of Science, Cochrane Library and EMBASE databases. Pooled HRs and 95% CIs were then employed as effect sizes. RESULTS: Seven studies comprising 1244 patients were pooled. Elevated pretreatment SF was associated with worse overall survival (OS) (HR 1.60, 95% CI 1.36 to 1.88, p<0.001) and recurrence-free survival/progression-free survival/time to recurrence (HR 1.70, 95% CI 1.15 to 2.52, p=0.008). Significant prognostic value of elevated pretreatment SF on OS was detected in the subgroups regardless of the cancer type, race, SF cut-off value, tumour-node-metastasis stage and Newcastle-Ottawa Scale score. CONCLUSION: Elevated pretreatment SF was associated with worse survival outcome of patients with HBP cancers. As such, it may serve as a novel prognostic biomarker for HBP cancers.

Clinicopathological and prognostic value of preoperative lymphocyte to monocyte ratio for hepatocellular carcinoma following curative resection: A meta-analysis including 4,092 patients.

BACKGROUND: Previous studies have reported that lymphocyte-to-monocyte ratio (LMR) had novel prognostic value in hepatocellular carcinoma (HCC). The purpose of this meta-analysis was to synthetically evaluate the prognostic role of preoperative LMR in HCC patients following curative resection. METHODS: Eligible studies were acquired through searching Pubmed, Web of Science, Cochrane Library and EMbase update to September 2019. Merged hazard ratios (HRs) and 95% confidence intervals (CIs) were applied as effect sizes. RESULTS: A total of ten studies containing 4,092 patients following liver resection were enrolled in this meta-analysis. The pooled results demonstrated that preoperative elevated LMR indicated superior survival outcome (HR: 0.58, 95% CI: 0.34-0.96, P = .035) and recurrence-free survival (RFS)/disease-free survival/time to recurrence (HR = 0.76, 95% CI: 0.58-0.98, P = .034). The significant prognostic role of preoperative LMR was detected in the subgroup of all publication year, country of origin, sample sizes <300, TNM stage of I-IV and LMR cut-off value ≤4. Furthermore, high LMR was significantly associated with male, high AFP, large tumor size, incomplete tumor capsule, advanced TNM stage and BCLC stage, and presence of PVTT. CONCLUSION: Elevated preoperative LMR indicated superior survival outcome in HCC patients following curative resection, and might serve as a novel prognostic biomarker.